Cargando…

Stratified survival of resected and overall pancreatic cancer patients in Europe and the USA in the early twenty-first century: a large, international population-based study

BACKGROUND: The prognosis of pancreatic cancer (PaC) strongly varies across different stages and age groups, which has unfortunately not been well recorded in the literature. This international population-based study aimed to provide tumor-node-metastasis (TNM) stage- and age-specific survival estim...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Lei, Jansen, Lina, Balavarca, Yesilda, Babaei, Masoud, van der Geest, Lydia, Lemmens, Valery, Van Eycken, Liesbet, De Schutter, Harlinde, Johannesen, Tom B., Primic-Žakelj, Maja, Zadnik, Vesna, Besselink, Marc G., Schrotz-King, Petra, Brenner, Hermann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6102804/
https://www.ncbi.nlm.nih.gov/pubmed/30126408
http://dx.doi.org/10.1186/s12916-018-1120-9
_version_ 1783349240917917696
author Huang, Lei
Jansen, Lina
Balavarca, Yesilda
Babaei, Masoud
van der Geest, Lydia
Lemmens, Valery
Van Eycken, Liesbet
De Schutter, Harlinde
Johannesen, Tom B.
Primic-Žakelj, Maja
Zadnik, Vesna
Besselink, Marc G.
Schrotz-King, Petra
Brenner, Hermann
author_facet Huang, Lei
Jansen, Lina
Balavarca, Yesilda
Babaei, Masoud
van der Geest, Lydia
Lemmens, Valery
Van Eycken, Liesbet
De Schutter, Harlinde
Johannesen, Tom B.
Primic-Žakelj, Maja
Zadnik, Vesna
Besselink, Marc G.
Schrotz-King, Petra
Brenner, Hermann
author_sort Huang, Lei
collection PubMed
description BACKGROUND: The prognosis of pancreatic cancer (PaC) strongly varies across different stages and age groups, which has unfortunately not been well recorded in the literature. This international population-based study aimed to provide tumor-node-metastasis (TNM) stage- and age-specific survival estimates and trends in resected and overall (resected and unresected) PaC in the early twenty-first century. METHODS: Using data from the US Surveillance, Epidemiology, and End Results-18 Program and the national cancer registries of the Netherlands, Belgium, Norway, and Slovenia, short-term and long-term overall survival results stratified by TNM stage and age in resected and overall primary PaC, irrespective of being microscopically confirmed or not, in 2003–2014 were computed using the Kaplan-Meier method. The temporal survival trends over three predefined periods (2003–2005, 2006–2008, and 2009–2011) were further examined using the log-rank test. RESULTS: In total, data for 125,183 patients were analyzed. Overall, age-stratified 3-year survival was 20–34% (< 60 years), 14–25% (60–69 years), and 9–13% (≥ 70 years) in stages I–II PaC; and 2–5% (< 60 years), 1–2% (60–69 years), and < 1–1% (≥ 70 years) in stages III–IV cancer. Patients who underwent operation had higher 3-year survival in each stage and age group (stages I–II: 23–39% (< 60 years), 16–31% (60–69 years), and 17–30% (≥ 70 years); stages III–IV: 5–19% (< 70 years) and 2–14% (≥ 70 years)). Perioperative survival also decreased with advancing stage and older age (stages I–II: 98–100% (< 60 years), 97–99% (60–69 years), and 94–99% (≥ 70 years); stages III–IV: 94–99% (< 70 years) and 81–96% (≥ 70 years)). Between 2003 and 2005 and 2009–2011, for overall PaC, both short-term and long-term survival improvements were observed in all countries except Belgium; for resected disease, short-term improvements were present only in the USA and Slovenia, but long-term improvements were observed in all countries except Slovenia, with stage-specific variations. CONCLUSIONS: Our large international study provides TNM stage- and age-specific population-based survival in overall and resected PaC that will facilitate clinical counseling. While the survival expectations for patients with resected PaC are substantially higher than the widely available and known dismal survival predictions for overall patients, conclusions on the benefits of resection cannot be made from this observational study. Patients with advanced-stage disease and/or older age should undergo careful risk assessment before treatment. Limited but inspiring improvement in survival is observed. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12916-018-1120-9) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6102804
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-61028042018-08-27 Stratified survival of resected and overall pancreatic cancer patients in Europe and the USA in the early twenty-first century: a large, international population-based study Huang, Lei Jansen, Lina Balavarca, Yesilda Babaei, Masoud van der Geest, Lydia Lemmens, Valery Van Eycken, Liesbet De Schutter, Harlinde Johannesen, Tom B. Primic-Žakelj, Maja Zadnik, Vesna Besselink, Marc G. Schrotz-King, Petra Brenner, Hermann BMC Med Research Article BACKGROUND: The prognosis of pancreatic cancer (PaC) strongly varies across different stages and age groups, which has unfortunately not been well recorded in the literature. This international population-based study aimed to provide tumor-node-metastasis (TNM) stage- and age-specific survival estimates and trends in resected and overall (resected and unresected) PaC in the early twenty-first century. METHODS: Using data from the US Surveillance, Epidemiology, and End Results-18 Program and the national cancer registries of the Netherlands, Belgium, Norway, and Slovenia, short-term and long-term overall survival results stratified by TNM stage and age in resected and overall primary PaC, irrespective of being microscopically confirmed or not, in 2003–2014 were computed using the Kaplan-Meier method. The temporal survival trends over three predefined periods (2003–2005, 2006–2008, and 2009–2011) were further examined using the log-rank test. RESULTS: In total, data for 125,183 patients were analyzed. Overall, age-stratified 3-year survival was 20–34% (< 60 years), 14–25% (60–69 years), and 9–13% (≥ 70 years) in stages I–II PaC; and 2–5% (< 60 years), 1–2% (60–69 years), and < 1–1% (≥ 70 years) in stages III–IV cancer. Patients who underwent operation had higher 3-year survival in each stage and age group (stages I–II: 23–39% (< 60 years), 16–31% (60–69 years), and 17–30% (≥ 70 years); stages III–IV: 5–19% (< 70 years) and 2–14% (≥ 70 years)). Perioperative survival also decreased with advancing stage and older age (stages I–II: 98–100% (< 60 years), 97–99% (60–69 years), and 94–99% (≥ 70 years); stages III–IV: 94–99% (< 70 years) and 81–96% (≥ 70 years)). Between 2003 and 2005 and 2009–2011, for overall PaC, both short-term and long-term survival improvements were observed in all countries except Belgium; for resected disease, short-term improvements were present only in the USA and Slovenia, but long-term improvements were observed in all countries except Slovenia, with stage-specific variations. CONCLUSIONS: Our large international study provides TNM stage- and age-specific population-based survival in overall and resected PaC that will facilitate clinical counseling. While the survival expectations for patients with resected PaC are substantially higher than the widely available and known dismal survival predictions for overall patients, conclusions on the benefits of resection cannot be made from this observational study. Patients with advanced-stage disease and/or older age should undergo careful risk assessment before treatment. Limited but inspiring improvement in survival is observed. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12916-018-1120-9) contains supplementary material, which is available to authorized users. BioMed Central 2018-08-21 /pmc/articles/PMC6102804/ /pubmed/30126408 http://dx.doi.org/10.1186/s12916-018-1120-9 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Huang, Lei
Jansen, Lina
Balavarca, Yesilda
Babaei, Masoud
van der Geest, Lydia
Lemmens, Valery
Van Eycken, Liesbet
De Schutter, Harlinde
Johannesen, Tom B.
Primic-Žakelj, Maja
Zadnik, Vesna
Besselink, Marc G.
Schrotz-King, Petra
Brenner, Hermann
Stratified survival of resected and overall pancreatic cancer patients in Europe and the USA in the early twenty-first century: a large, international population-based study
title Stratified survival of resected and overall pancreatic cancer patients in Europe and the USA in the early twenty-first century: a large, international population-based study
title_full Stratified survival of resected and overall pancreatic cancer patients in Europe and the USA in the early twenty-first century: a large, international population-based study
title_fullStr Stratified survival of resected and overall pancreatic cancer patients in Europe and the USA in the early twenty-first century: a large, international population-based study
title_full_unstemmed Stratified survival of resected and overall pancreatic cancer patients in Europe and the USA in the early twenty-first century: a large, international population-based study
title_short Stratified survival of resected and overall pancreatic cancer patients in Europe and the USA in the early twenty-first century: a large, international population-based study
title_sort stratified survival of resected and overall pancreatic cancer patients in europe and the usa in the early twenty-first century: a large, international population-based study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6102804/
https://www.ncbi.nlm.nih.gov/pubmed/30126408
http://dx.doi.org/10.1186/s12916-018-1120-9
work_keys_str_mv AT huanglei stratifiedsurvivalofresectedandoverallpancreaticcancerpatientsineuropeandtheusaintheearlytwentyfirstcenturyalargeinternationalpopulationbasedstudy
AT jansenlina stratifiedsurvivalofresectedandoverallpancreaticcancerpatientsineuropeandtheusaintheearlytwentyfirstcenturyalargeinternationalpopulationbasedstudy
AT balavarcayesilda stratifiedsurvivalofresectedandoverallpancreaticcancerpatientsineuropeandtheusaintheearlytwentyfirstcenturyalargeinternationalpopulationbasedstudy
AT babaeimasoud stratifiedsurvivalofresectedandoverallpancreaticcancerpatientsineuropeandtheusaintheearlytwentyfirstcenturyalargeinternationalpopulationbasedstudy
AT vandergeestlydia stratifiedsurvivalofresectedandoverallpancreaticcancerpatientsineuropeandtheusaintheearlytwentyfirstcenturyalargeinternationalpopulationbasedstudy
AT lemmensvalery stratifiedsurvivalofresectedandoverallpancreaticcancerpatientsineuropeandtheusaintheearlytwentyfirstcenturyalargeinternationalpopulationbasedstudy
AT vaneyckenliesbet stratifiedsurvivalofresectedandoverallpancreaticcancerpatientsineuropeandtheusaintheearlytwentyfirstcenturyalargeinternationalpopulationbasedstudy
AT deschutterharlinde stratifiedsurvivalofresectedandoverallpancreaticcancerpatientsineuropeandtheusaintheearlytwentyfirstcenturyalargeinternationalpopulationbasedstudy
AT johannesentomb stratifiedsurvivalofresectedandoverallpancreaticcancerpatientsineuropeandtheusaintheearlytwentyfirstcenturyalargeinternationalpopulationbasedstudy
AT primiczakeljmaja stratifiedsurvivalofresectedandoverallpancreaticcancerpatientsineuropeandtheusaintheearlytwentyfirstcenturyalargeinternationalpopulationbasedstudy
AT zadnikvesna stratifiedsurvivalofresectedandoverallpancreaticcancerpatientsineuropeandtheusaintheearlytwentyfirstcenturyalargeinternationalpopulationbasedstudy
AT besselinkmarcg stratifiedsurvivalofresectedandoverallpancreaticcancerpatientsineuropeandtheusaintheearlytwentyfirstcenturyalargeinternationalpopulationbasedstudy
AT schrotzkingpetra stratifiedsurvivalofresectedandoverallpancreaticcancerpatientsineuropeandtheusaintheearlytwentyfirstcenturyalargeinternationalpopulationbasedstudy
AT brennerhermann stratifiedsurvivalofresectedandoverallpancreaticcancerpatientsineuropeandtheusaintheearlytwentyfirstcenturyalargeinternationalpopulationbasedstudy